BRIEF-GSK asthma drug meets main goal in safety study – Reuters

BRIEF-GSK asthma drug meets main goal in safety study
Reuters
Oct 27 Glaxosmithkline Plc. * GSK's Advair Diskus achieves primary endpoint in LABA safety study of patients with asthma. * Results from study showed FSC twice-daily demonstrated non-inferiority compared to corresponding doses of FP twice-daily.

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.